PGS Publication: PGP000450

Publication Information (EuropePMC)
Title Genetic Risk Score Improves Risk Stratification for Anticoagulation-Related Intracerebral Hemorrhage.
PubMed ID 36756894(Europe PMC)
doi 10.1161/strokeaha.122.041764
Publication Date Feb. 9, 2023
Journal Stroke
Author(s) Mayerhofer E, Parodi L, Prapiadou S, Malik R, Rosand J, Georgakis MK, Anderson CD.
Released in PGS Catalog: March 24, 2023

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS003457
(GRS_ICH)
PGP000450 |
Mayerhofer E et al. Stroke (2023)
Intracerebral hemorrhage intracerebral hemorrhage 682,890
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003457/ScoringFiles/PGS003457.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM017258 PGS003457
(GRS_ICH)
PSS010179|
Multi-ancestry (including European)|
5,530 individuals
PGP000450 |
Mayerhofer E et al. Stroke (2023)
Reported Trait: Incident intracerebral hemorrhage in anticoagulation therapy HR: 1.24 [1.01, 1.53] : 0.02 age at baseline (controls) or ICH event (cases), sex, PC1 to 10, and genotyping array
PPM017259 PGS003457
(GRS_ICH)
PSS010179|
Multi-ancestry (including European)|
5,530 individuals
PGP000450 |
Mayerhofer E et al. Stroke (2023)
Reported Trait: Incident intracerebral hemorrhage in anticoagulation therapy HR: 1.33 [1.11, 1.59] C-index: 0.57 [0.5, 0.64] age at baseline (controls) or ICH event (cases), sex, PC1 to 10, and genotyping array, clinical risk score

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS010179 The test cohort consisted of individuals without a history of ICH at baseline and anticoagulant use defined by self-report in the verbal interview at inclusion. Furthermore, individuals were included if they had a diagnosis of the International Classification of Diseases, Tenth Revision code Z92.1 (personal history of long-term (current) use of anticoagulants) or D68.3 (hemorrhagic disorder due to circulating anticoagulants) at baseline or a prescription of an anticoagulant medication between baseline and 6 months thereafter in the primary care data Mean = 11.9 years
[
  • 86 cases
  • , 4,972 controls
]
,
69.0 % Male samples
Mean = 62.0 years European UKB
PSS010179 The test cohort consisted of individuals without a history of ICH at baseline and anticoagulant use defined by self-report in the verbal interview at inclusion. Furthermore, individuals were included if they had a diagnosis of the International Classification of Diseases, Tenth Revision code Z92.1 (personal history of long-term (current) use of anticoagulants) or D68.3 (hemorrhagic disorder due to circulating anticoagulants) at baseline or a prescription of an anticoagulant medication between baseline and 6 months thereafter in the primary care data Mean = 11.9 years
[
  • 8 cases
  • , 464 controls
]
,
69.0 % Male samples
Mean = 62.0 years Not reported UKB